此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of a New Induction and Dosing Schedule for Sublocade in Opioid Use Disorder (BRIDGE)

2026年11月16日 更新者:Dr. Navneet Singh Khosa、The Smart Clinic

BRIDGE Study: Buprenorphine XR Real-world Induction, Dosing, and Gradual Evaluation

This study is looking at a new way to start Sublocade, a monthly injectable medicine already approved in Canada for opioid use disorder. Right now, most people start Sublocade with two doses of 300 mg, one month apart. This study is testing a different, more gradual approach: a smaller dose (50 mg) on Day 1, a second small dose (50 mg) on Day 7, and then the regular dose (300 mg) on Day 14.

The study team wants to find out whether this gradual approach helps people transitioning from methadone, or people who have used buprenorphine before, get started on treatment more easily. Everyone in the study follows the same schedule, and no one gets a placebo (an inactive treatment).

Participants will get study visits on Day 1, Day 7, and Day 14, along with short daily check-ins about how they're feeling for about 4 weeks, and some questionnaires about their quality of life and treatment satisfaction. The study is being done at one clinic in Calgary, Alberta.

研究概览

地位

尚未招聘

条件

干预/治疗

详细说明

Sublocade (buprenorphine extended-release) is a Health Canada-approved subcutaneous injection for the management of moderate to severe opioid use disorder in adults (DIN 02483084, 100 mg; DIN 02483092, 300 mg). The currently approved induction regimen consists of 300 mg for the first injection and 300 mg for the second injection, administered one month apart, with subsequent monthly maintenance dosing.

This study evaluates a modified induction and titration schedule intended to characterize an alternative approach for patients transitioning from methadone treatment or with prior buprenorphine exposure. Participants receive 50 mg on Day 1, 50 mg on Day 7, and 300 mg on Day 14, using the same approved product and formulation, prepared via partial-volume administration from the 100 mg pre-filled syringe for the Day 1 and Day 7 doses.

The primary objective is to determine the proportion of participants who complete this induction schedule without discontinuation due to withdrawal symptoms or adverse events. Secondary objectives include characterizing daily withdrawal symptom trajectory (via the Subjective Opiate Withdrawal Scale), and changes in Addiction Severity Index, Quality of Life, PROPr health utility, and Treatment Satisfaction scores from baseline to Week 4.

This is a prospective, single-arm, open-label interventional study with no randomization or control arm; outcomes are compared descriptively to existing standard-of-care induction practice as a historical reference. The study is conducted at a single site (The Smart Clinic, Calgary, Alberta) with a planned enrollment of 50-100 adult participants.

研究类型

介入性

注册 (估计的)

100

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Navneet Singh Khosa, MD
  • 电话号码:403-769-0111
  • 邮箱:nkhosa@smartc.ca

研究联系人备份

  • 姓名:Ravneet Kaur Sidhu, BSN
  • 电话号码:4037690111
  • 邮箱:rsidhu@smartc.ca

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Currently receiving methadone treatment, OR active opioid use disorder with prior exposure to buprenorphine
  • Willingness and ability to provide informed consent to participate

Exclusion Criteria:

  • No diagnosis of opioid use disorder and no prior buprenorphine exposure
  • Known intolerance or hypersensitivity to buprenorphine

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Modified Induction Schedule

All participants receive buprenorphine extended-release (Sublocade) by subcutaneous injection: 50 mg on Day 1, 50 mg on Day 7, and 300 mg on Day 14.

Sublocade (buprenorphine extended-release), a Health Canada-approved subcutaneous injection (DIN 02483084, 100 mg; DIN 02483092, 300 mg). Administered as 50 mg on Day 1, 50 mg on Day 7, and 300 mg on Day 14.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Induction Completion Rate
大体时间:Day 14

Proportion of participants who complete the Day 1, Day 7, and Day 14 dosing schedule without discontinuation due to withdrawal symptoms or adverse events.

Day 14

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 学习椅:Jospeh Tcherkezian, PHD、SMART Clinic

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年8月31日

研究完成 (估计的)

2027年12月1日

研究注册日期

首次提交

2026年11月16日

首先提交符合 QC 标准的

2026年11月16日

首次发布 (实际的)

2026年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • HREBA.CTC-26-0111

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

No formal individual participant data (IPD) sharing plan has been established for this study at this time. This is a single-site, investigator-initiated study, and any future decision regarding data sharing would need to account for participant privacy protections under Alberta's Health Information Act and Personal Information Protection Act, as well as the terms of the study's funding agreement with Indivior Canada Inc.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.